Paclitaxel as continuation maintenance therapy in patients with advanced non-small cell lung cancer

Gohar, Suzy; Aziz, Khaled Abd El; Bary, Naser Abd El; Shehata, Mohamed; Alhassanin, Suzan; Hegazy, Ahmed

doi:10.1093/annonc/mdz437.036

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Their findings provide guidance for the design and optimization of future mRNA cancer vaccines. The chemotherapeutic drug docetaxel is commonly used in the treatment of many human malignancies, including nonsmall cell lung cancer, breast cancer, ovarian cancer, and hormone-refractory prostate cancer. − In one study, Fotin-Mleczek et al combined docetaxel with the two-component mRNA vaccines which could encode OVA and induce self-adjuvant action via TLR-7 pathway, leading to a significant delay of tumor growth and more effective antitumor capacity, whether compared to OVA mRNA vaccination or chemotherapeutic drugs alone . Similar results were also observed when they combined cisplatin with two-component mRNA vaccines.…”

Section: Strategies To Enhance the Efficacy Of Mrna Cancer Vaccinesmentioning

confidence: 78%

mRNA Cancer Vaccines: Construction and Boosting Strategies

Liu,

Huang,

Yang

et al. 2023

ACS Nano

View full text Add to dashboard Cite

In late 2020, the U.S. Food and Drug Administration (FDA) approved a lipid-based mRNA vaccine for the prevention of COVID-19, which has pushed this field to be more closely studied and motivated researchers to delve deeper into mRNA therapeutics. To date, the research on mRNA cancer vaccines has been developed rapidly, and substantial hopeful therapeutic results have been achieved against various solid tumors in clinical trials. In this review, we first introduce three main components of mRNA cancer vaccines, including mRNA antigens, adjuvants, and delivery vectors. Engineering these components can optimize the therapeutic effects of mRNA cancer vaccines. For instance, appropriate modification of mRNA structure can alleviate the poor stability and innate immunogenicity of mRNA, and the use of mRNA delivery vectors can address the issues of low delivery efficiency in vivo. Second, we emphatically discuss some strategies to further improve the efficacy of mRNA cancer vaccines, namely modulating the immunosuppressive tumor environment, optimizing administration routes, achieving targeting delivery to intended tissues or organs, and employing combination therapy. These strategies can strengthen the tumor inhibitory ability of mRNA cancer vaccines and increase the possibility of tumor elimination. Finally, we point out some challenges in the clinical practice of mRNA cancer vaccines and offer our perspectives on future developments in this rapidly evolving field. It is anticipated that mRNA cancer vaccines will be rapidly developed for clinical cancer therapy in the near future.

show abstract